This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cell Therapeutics Must Deliver on Promise for Myelofibrosis Drug Partner

CTIC Chart CTIC data by YCharts

SEATTLE ( TheStreet) -- Cell Therapeutics (CTIC - Get Report) CEO Jim Bianco has told investors -- including the hedge funds which bought his last fund-raising deal in September -- that he'll land a partner for the company's experimental myelofibrosis drug before the end of the year.

That's the next big catalyst for the company, and it helps explain why Cell Therapeutics shares closed Monday at $1.95, a 52-week high.

Cell Therapeutics is famous -- I should say infamous -- for drug development futility. Few companies in the biopharma world have lost as much money ($1.9 billion) for as long (22 years) as Cell Therapeutics. Yet Cell Therapeutics refuses to die, mostly due to Bianco's uncanny ability to emerge unscathed from failure while coaxing cash from another group of investors with promises that "the next drug" will finally work out.

Bianco's next, next drug is pacritinib, an oral Jak-2 inhibitor for myelofibrosis which Cell Therapeutics bought in 2012 from Singapore's S-Bio for $30 million upfront, half of that in stock. Onyx Pharmaceuticals once owned development rights to pacritinib but returned it to S-Bio for reasons never fully disclosed. That's why Cell Therapeutics was able to pick up pacritinib cheap, especially for a drug phase III ready.

Consider Gilead Sciences (GILD - Get Report) paid $500 million to acquire YM BioSciences and its phase III-ready myelofibrosis drug CYT387, now renamed momelotinib. The myelofibrosis treatment market is already served by Jakafi, marketed by Incyte (INCY - Get Report) and Novartis (NVS - Get Report).

With the exception of Pixuvri (which barely counts), Cell Therapeutics has never developed a cancer drug successfully on its own. All of the company's past, phase III cancer drug clinical trials have either failed or been stopped prematurely.

This is why Bianco's promise to find a development and marketing partner for pacritinib is so important. No one wants Cell Therapeutics to be chiefly responsible for conducting the pacritinib clinical trials because -- let's be frank -- the company will screw them up.

Pacritinib has baggage that makes people doubt the drug's clinical and commercial potential. Cell Therapeutics licensing and developing the drug doesn't help, either. But investors might start to look at pacritinib differently if a company with a solid reputation and track record in cancer drug development signs on as Cell Therapeutics' partner.

A trustworthy partner doesn't guarantee pacritinib's success but it would validate the drug to some degree.

Cell Therapeutics has already started the first pacritinib phase III myelofibrosis clinical trial. On Monday, the company announced an agreement with the FDA on the design for the second trial.

The clock is ticking. Bianco needs to deliver the partner.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $0.50 0.00%
GILD $88.21 0.00%
INCY $72.27 0.00%
NVS $75.97 0.00%
AAPL $93.74 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs